#ShockwaveIVL’s# clinical evidence is different. Our predictably safe and consistently effective MOA has been validated by nearly 25,000 published patient outcomes across more than 600 scientific publications. To date, we have supported more than 70 company-led and investigator-initiated clinical studies, with an additional 50 planned between 2025 and 2029. Each study is designed to reflect the complex scenarios physicians encounter every day and to generate the clinical evidence needed to support confident adoption of Shockwave IVL. Read this new Cardiac Interventions Today article by our CMO, Nick West, to learn what our relentless commitment to research means for the future of calcium modification:  US Rx only. Safety Info:  availability may vary by country.